Endpoints used in phase III randomized controlled trials of treatment options for COVID-19
EClinicalMedicine
.
2020 Jun 2:23:100403.
doi: 10.1016/j.eclinm.2020.100403.
eCollection 2020 Jun.
Authors
Aakash Desai
1
,
Bishal Gyawali
2
3
4
Affiliations
1
Deparment of Medicine, University of Connecticut, Farmington, CT 06030, United States.
2
Department of Oncology, Queen's University, Kingston, Canada.
3
Department of Public Health Sciences, Queen's University, Kingston, Canada.
4
Division of Cancer Care and Epidemiology, Queen's University, Kingston, Canada.
PMID:
32632415
PMCID:
PMC7265861
DOI:
10.1016/j.eclinm.2020.100403
No abstract available